Mouse Brain PI3K/Akt MAPK/ERK1/2 Hippocampus Individuals with fragile X syndrome (FXS), an inherited form of cognitive disability, have a wide range of symptoms including hyperactivity, autistic behavior, seizures and learning deficits. FXS is caused by silencing of FMR1 and the consequent absence of fragile X mental retardation protein (FMRP). FMRP is an RNA-binding protein that associates with polyribosomes and negatively regulates translation. In a previous study of a mouse model of FXS (Fmr1 knockout (KO)) we demonstrated that in vivo rates of cerebral protein synthesis (rCPS) were elevated in selective brain regions suggesting that the absence of FMRP in FXS may result in dysregulation of cerebral protein synthesis. Lithium, a drug used clinically to treat bipolar disorder, has been used to improve mood dysregulation in individuals with FXS. We reported previously that in the Fmr1 KO mouse chronic dietary lithium treatment reversed or ameliorated both behavioral and morphological abnormalities. Herein we report that chronic dietary lithium treatment reversed the increased rCPS in Fmr1 KO mice with little effect on wild type mice. We also report our results of analyses of key signaling molecules involved in regulation of mRNA translation. Our analyses indicate that neither effects on the PI3K/Akt nor the MAPK/ERK 1/2 pathway fully account for the effects of lithium treatment on rCPS. Collectively our findings and those from other laboratories on the efficacy of lithium treatment in animal models support further studies in patients with FXS.
Introduction
Individuals with fragile X syndrome (FXS), an inherited form of intellectual disability, show a broad spectrum of morphologic, cognitive, behavioral, neurological, and psychological features (Chonchaiya et al., 2009) . FXS is caused by the silencing of the FMR1 gene and the consequent absence of its protein product, fragile X mental retardation protein (FMRP) (Brown, 2002) . FMRP is a RNA-binding protein that associates with polyribosomes and negatively regulates translation of certain mRNAs (Penagarikano et al., 2007) . It is thought that absence of FMRP results in a dysregulation of protein synthesis and that it is this dysregulation that has such profound consequences for development and function of the nervous system. Protein synthesis in the nervous system is required for normal nervous system development and maintenance. It is also essential for implementation of long lasting changes in synaptic strength such as occur in long term potentiation (LTP) and long term depression (LTD). Some forms of both LTD and LTP are impaired in Fmr1 knockout (KO) mice (Huber et al., 2004; Larson et al., 2005; Li et al., 2002; Suvrathan et al., 2010; Wilson and Cox, 2007; Zhao et al., 2005) , and it has been proposed that a dysregulation of protein synthesis may underlie these impairments.
In accord with the idea that a dysregulation of protein synthesis may be at the heart of the defect in FXS, we have shown that adult male Fmr1 KO mice have elevated regional rates of cerebral protein synthesis (rCPS) compared with wild type (WT) littermates (Qin et al., 2005) . We measured rCPS in vivo with a quantitative autoradiographic method (Smith et al., 1988) . Effects were regionally selective occurring mainly in hippocampus, thalamus and hypothalamus. Other investigators have monitored the incorporation of 35 S-methionine/ cysteine into new protein in vitro. Their findings also indicate that incorporation is higher in hippocampal slices from Fmr1 KO mice (Dölen et al., 2007; Osterweil et al., 2010) .
Treatment for FXS is largely symptom-based and multidisciplinary. Current treatments include special education, behavioral interventions, physical therapy and symptom-directed pharmacotherapy. There are several classes of pharmacotherapeutic agents currently Abbreviations: FXS, fragile X syndrome; FMRP, fragile X mental retardation protein; rCPS, regional rate of cerebral protein synthesis; WT, wild type; KO, knock out; Akt, protein kinase B; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; ERK, extracellular-signal-regulated kinase; p70 S6K, p70 S6 kinase; PIKE, PI3K enhancer; 4E-BP1, eIF4E-binding protein.
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